Clinical trials: Malignant Melanomas
Advanced Cancer, Solid Tumor
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied.
- Trial name
- NCT01596140
- Testing
- Vemurafenib, Everolimus, Temsirolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Unresectable Melanoma
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.
- Conditions
- Melanoma, Unresectable Melanoma, Advanced Melanoma
- Trial name
- NCT03501368
- Testing
- Ceritinib, Trametinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898183
- Testing
- gene expression analysis, polymorphism analysis
- Volunteers
- 91 people
- Sponsor
- SWOG Cancer Research Network
Melanoma, Immunotoxicity
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Management of melanoma is based on primary excision of the tumor. In cases of melanoma with poor prognosis criteria, or when it is locally advanced or metastatic, there is an indication for the implementation of adjuvant therapy…
- Trial name
- APiTOXMM (NCT06627595)
- Testing
- Immunotherapy
- Where
- 2 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Melanoma, Metastases
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new…
- Trial name
- NCT00099970
- Testing
- M200 (volociximab) in Combination with Dacarbazine (DTIC)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- PDL BioPharma, Inc.
Melanoma
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
- Trial name
- NCT02905266
- Testing
- Nivolumab, Ipilimumab
- Where
- 16 sites in Australia, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Pigmented Lesions, Pigmented Skin Lesion
Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy
The aim of this study is to evaluate the imaging performance of Spectrally Encoded Confocal Microscopy (SECM) for imaging human skin and skin diseases.
- Conditions
- Pigmented Lesions, Pigmented Skin Lesion, Pigmented Moles, Skin Lesion
- Trial name
- NCT04566302
- Testing
- SECM Skin Imaging
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Melanoma
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04700072
- Testing
- Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Neoplasms, Melanoma
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM) in the treatment of metastatic melanoma that has…
- Trial name
- NCT00527657
- Testing
- Lomustine, Temozolomide, Thalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Immune Defect
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
Cutaneous melanoma is a bad prognosis skin cancer, which can be treated with immune checkpoint inhibitors (ICI), such as anti-PD-1 (nivolumab, nivo) and anti-CTLA-4 (ipilimumab, ipi).
- Conditions
- Melanoma, Immune Defect, Tumor Skin
- Trial name
- ATPIC (NCT05867004)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Claudius Regaud
Melanoma
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
- Trial name
- NCT04370704
- Testing
- INCAGN02385, INCAGN02390, INCMGA00012.
- Where
- 17 sites in United States, Australia
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01940809
- Testing
- Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Colitis, Lung Non-Small Cell Carcinoma
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
This phase I/II trial studies the side effects of infliximab and vedolizumab and to see how well they work in treating inflammation of the colon (colitis) caused by immune checkpoint inhibitor therapy in patients with cancer of…
- Conditions
- Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04407247
- Testing
- Infliximab, Vedolizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Skin, Melanoma Stage Iii
MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]
The goal of this observational study is to learn about if new biomarkers such as gut microbiota and molecular genetics melanoma features could predict clinical radiological and pathological response to neoadjuvant monotherapy…
- Trial name
- CRISTINA (NCT06299878)
- Testing
- Gut microbiota analysis
- Where
- Russia
- Volunteers
- 72 people
- Sponsor
- Russian Academy of Medical Sciences
Mucosal Melanoma, Recurrent Melanoma
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT01961115
- Testing
- Epacadostat, MELITAC 12.1 Peptide Vaccine
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
- Trial name
- NCT01123304
- Testing
- MORAb028
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Morphotek
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Melanoma, Stage III Melanoma
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg.
- Trial name
- NCT00003789
- Testing
- isolated limb perfusion, melphalan, recombinant tumor necrosis factor family protein
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
T-cell Based Immunotherapy for of Melanoma
The aim of this study is to investigate the toxicity and clinical response of therapy with tumor infiltrating lymphocytes as treatment for advanced melanoma.
- Trial name
- NCT00937625
- Testing
- cyclophosphamide, fludarabine, T-cells, Interleukin-2
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Inge Marie Svane
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.